课题基金 / 基金详情

Novel Drug Targeting of the Circadian Factor REV-ERB Limits Infarct Expansion and Remodelling After Myocardial Ischemia/Reperfusion

Novel Drug Targeting of the Circadian Factor REV-ERB Limits Infarct Expansion and Remodelling After Myocardial Ischemia/Reperfusion
靶向昼夜节律因子 REV-ERB 的新药可限制心肌缺血/再灌注后的梗塞扩张和重塑
批准号:
369619
负责人:
Martino Tami
金额:
$47.09万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-09-01 至 2022-09-01

项目摘要

项目成果

Martino Tami的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ischemic heart disease leading to myocardial infarction (MI, heart attack) is a leading cause of death worldwide. Although many patients reach hospitals in a timely manner and undergo post-ischemia reperfusion (mI/R), this triggers a profound inflammatory
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-Clinical Translation of Circadian Biology to Benefit Treatment of Heart Disease
  • 批准号:
    354400
  • 项目类别:
    Operating Grants
  • 资助金额:
    $68.27万
  • 财政年份:
    2016
  • 负责人:
    Martino Tami
  • 依托单位:
Circadian Control of Cardiac Remodeling
  • 批准号:
    238301
  • 项目类别:
    Operating Grants
  • 资助金额:
    $24.44万
  • 财政年份:
    2011
  • 负责人:
    Martino Tami
  • 依托单位:
海外基金